Utilizing (18)F-FDG PET/CT Imaging for Enhanced Staging and Treatment Decisions in Pediatric Rhabdomyosarcoma

Introduction: Rhabdomyosarcoma(RMS) treatment is guided by an initial risk assessment.Standard diagnostic imaging like CT, MRI, and bone scan are used for staging.( 18)F-FDGPET-scan has the potential to optimize RMS staging by functional assessment.We aim to evaluate the role of PET/CT scans in RMS staging and treatment decisions. Methodology:We conducted a retrospective analysis on pediatric patients under the age of 18 years with RMS from May 2018 to December 2023.Patient demographics, PET/CT-scan findings at diagnosis, and impact on treatment decisions were assessed.All patients were thoroughly discussed in an MDT. Results:We identified 57 patients with RMS who underwent PET/CTscan at the time of diagnosis (median age 5.5 years; range,0.1-18).Head and neck non-para-meningeal (n=17,30%) and para-meningeal (n=12,21%) were the most common primaries.Thirty-nine patients(68%) had embryonal subtypes, and metastasis was present at diagnosis in thirteen(23%).Eleven patients had had surgery prior to referral: seven patients had negative PET/CT scans, three had uptake at the site of primary, and two at lymph nodes(LN).Among the remaining 46, PET/CTscan detected distant metastatic sites in three and confirmed suspicion of metastasis in one.Eight patients underwent LN biopsies due to PET/CT findings, and five of them showed disease positivity.The PET/CT scan findings at diagnosis influenced management decisions in 14 patients, resulting in changes in the radiotherapy field(n=9), risk group (n=2), or the decision to administer radiotherapy(n=3).PET/CT scans aligned with other diagnostic Methodology: in all patients except three: two exhibited suspicious LN involvement via MRI/CT-scans but were negative according to PET/CT scans and biopsies, while the third patient's scans did not indicate LN involvement, which was confirmed positive by PET-scan and biopsy.